Primary Care/Hospitalist
RSSArticles
-
Niacin and Coronary Heart Disease
Among patients with coronary heart disease and LDL-cholesterol levels less than 70 mg/dL, there is no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up, despite improvements in HDL-cholesterol and triglyceride levels. -
Clinical Briefs By Louis Kuritzky, MD
There is still some debate about the relationship between being overweight and cardiovascular (CV) health, since among overweight individuals there is great diversity in levels of CV fitness as well as CV risk factors (e.g., hypertension, diabetes, dyslipidemia). -
Internal Medicine Alert - Full February 15, 2012 Issue in PDF
-
ECG Review: Why is the QRS Wide?
Right-sided MCL-1 monitoring lead rhythm strip. Why might beats #4 through #7 be wide? -
Glucarpidase for Injection (Voraxaze®)
A drug has been approved to treat high plasma levels of methotrexate. Glucarpidase is a bacterial enzyme produced by recombinant DNA technology using genetically modified Exherichia coli. Glucarpidase is a carboxypeptidase enzyme that metabolizes methotrexate to its inactive metabolites. It is marketed by BTG International Inc. as Voraxaze. -
The Changing Heart Rate May Hold the Key to Life
In people without known cardiovascular disease, an increase in resting heart rate with age was associated with an increased risk of death. -
Emergency Medicine Reports - Full February 27, 2012 Issue in Streaming Audio/Downloadable MP3 Format
-
Update on Current Management of Atrial Fibrillation
Atrial fibrillation (AF) is an irregular, disorganized, electrical activity of the atria. It is characterized by uncoordinated atrial activity that leads to inefficient atrial contraction and impaired ventricular filling. -
Emergency Medicine Reports - Full February 27, 2012 Issue in PDF
-
Contraceptive Technology Update April 2012 Issue in PDF